Topical Lipid-Based Nanosphere Delivery System for Enhanced Docetaxel Administration

Abstract

        Lipo-Nanospheres (LPNS) can increase the bioavailability of poorly soluble medicines as an alternative to traditional lipid-bioactive nanocarriers. This novel lipid carrier is characterized by inexpensive components with improving biocompatibility and drug release. The primary goal is to choose the best lipid matrix and  transform these poorly soluble molecules into perhaps beneficial transdermal film ; by utilizing the new lipid nano carrier's capabilities of solubilize or disperse the drug in the solid lipid matrix internal core; then incorporated in polyvinyl alcohol transdermal film matrix . The drug used in this study was docetaxel(DCX) , which falls under Class IV of the Biopharmaceutical classification system (BCS) as a dissolution-limited drug. Emulsion melt dispersion was the most effective way to prepare DCX - LPNS. In conclusion, formula 9, which is made up of tristearin,  hydrogenated soybean oil and 90G phospholipid, gave the best drug dissolution, which led to the biggest results over 24 hours (98.43±0.829) with a particle size of 156.09±9.564nm. Zeta potential -23.5, drug content 93.56±1.33 and  drug loading capacity 6.59±0.04%, are a few advantages of the encapsulation technique ; improve the proper docetaxel incorporation within the lipo-nanosphere, while FESEM provides spherical particles with enhanced mechanical properties. Although FESEM and X-ray diffraction demonstrate that DCX was effectively contained in its amorphous form inside the LPNS. While the histological study determined the safety of the topical DCX-LPNS transdermal film, F12 with 10% PVA transdermal film matrix concentration produced the best sustained release in 24 hours, 89.84% with 90.8±0.19 drug content, transparent, flexible, and non-sticky appearance.